SCHEMBL2398352

SCHEMBL2398352

CN(Cc1cccc(C(F)(F)F)c1)C(=O)c1ncn(-c2cc(Cl)c(O)c(Cl)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 6/20 0.42
PDK1 Q15118 1/20 0.41
HSD17B13 Q7Z5P4 1/20 0.41
ALDH1A1 P00352 1/20 0.39
CCR1 P32246 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
KCNH2 Q12809 1/20 0.38
HSP90AA1 P07900 1/20 0.37
NOTUM Q6P988 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2402058 0.90 HSD17B13 (0.40) HSD17B13ALDH1A1CCR1TRPM8KCNH2
SCHEMBL2397910 0.88 NOTUM (0.39) HSD17B13ALDH1A1CCR1TRPM8KCNH2
SCHEMBL2220730 0.88 TRPM8 (0.41) PDK1HSD17B13ALDH1A1TRPM8KCNH2
SCHEMBL2401803 0.87 HSD17B13 (0.38) PDK1HSD17B13ALDH1A1CCR1TRPM8
SCHEMBL12262926 0.86 HSP90AA1 (0.52) PDK1HSP90AA1NOTUM
SCHEMBL2398017 0.86 HSD17B13 (0.38) HSD17B13ALDH1A1CCR1TRPM8KCNH2
SCHEMBL2396944 0.84 GRIN2B (0.40) HSD17B13TRPM8
SCHEMBL2399443 0.82 NOTUM (0.39) HSP90AA1NOTUM
SCHEMBL2398542 0.82 NOTUM (0.42) PDK1ALDH1A1HSP90AA1NOTUM
SCHEMBL2322717 0.81 HSD17B13 (0.44) PDK1HSD17B13TRPM8HSP90AA1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US claimed
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives CFTR, PKD1, PKD2 TACR1 102/4885PDK1 1005/4885HSD17B13 924/4885
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES CFTR, PKD1, PKD2 TACR1 155/4885PDK1 388/4885HSD17B13 2192/4885
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives CFTR, PKD1, PKD2 TACR1 102/4885PDK1 1005/4885HSD17B13 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.